Schizophrenia risk gene CAV1 is both pro-psychotic and required for atypical antipsychotic drug actions in vivo

Translational Psychiatry

Volumn 1, Issue , 2011, Pages

  Allen, J A ^a   Yadav, P N ^a   Setola, V ^a   Farrell, M ^a   Roth, B L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT2A; antipsychotic; caveolin; clozapine; schizophrenia

Indexed keywords

CAVEOLIN 1; NEUROLEPTIC AGENT; SEROTONIN 2A RECEPTOR;

ANIMAL; ANIMAL BEHAVIOR; ARTICLE; DISEASE MODEL; DRUG EFFECT; GENETICS; MOUSE; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CAVEOLIN 1; DISEASE MODELS, ANIMAL; MICE; MICE, KNOCKOUT; RECEPTOR, SEROTONIN, 5-HT2A; SCHIZOPHRENIA;

EID: 80052324943     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2011.35     Document Type: Article

References (36)

1. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460: 748-752.
2. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe'er I et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009; 460: 753-757.
3. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D et al. Common variants conferring risk of schizophrenia. Nature 2009; 460: 744-747.
4. Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S et al. Large recurrent microdeletions associated with schizophrenia. Nature 2008; 455: 232-236.
5. Jaaro-Peled H, Ayhan Y, Pletnikov MV, Sawa A. Review of pathological hallmarks of schizophrenia: Comparison of genetic models with patients and nongenetic models. Schizophr Bull 2010; 36: 301-313.
6. Karayiorgou M, Simon TJ, Gogos JA. 22q11.2 microdeletions: Linking DNA structural variation to brain dysfunction and schizophrenia. Nat Rev Neurosci 2010; 11: 402-416.
7. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 2008; 320: 539-543. (Pubitemid 351590668)
8. Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev 2004; 84: 1341-1379. (Pubitemid 39287953)
9. Ostrom RS. New determinants of receptor-effector coupling: Trafficking and compartmentation in membrane microdomains. Mol Pharmacol 2002; 61: 473-476. (Pubitemid 34171912)
10. Allen JA, Halverson-Tamboli RA, Rasenick MM. Lipid raft microdomains and neurotransmitter signalling. Nat Rev Neurosci 2007; 8: 128-140. (Pubitemid 46146951)
11. Francesconi A, Kumari R, Zukin RS. Regulation of group I metabotropic glutamate receptor trafficking and signaling by the caveolar/lipid raft pathway. J Neurosci 2009; 29: 3590-3602.
12. Boulware MI, Kordasiewicz H, Mermelstein PG. Caveolin proteins are essential for distinct effects of membrane estrogen receptors in neurons. J Neurosci 2007; 27: 9941-9950. (Pubitemid 47403995)
13. Heiman M, Schaefer A, Gong S, Peterson JD, Day M, Ramsey KE et al. A translational profiling approach for the molecular characterization of CNS cell types. Cell 2008; 135: 738-748.
14. Bhatnagar A, Sheffler DJ, Kroeze WK, Compton-Toth B, Roth BL. Caveolin-1 interacts with 5-HT2A serotonin receptors and profoundly modulates the signaling of selected Galphaqcoupled protein receptors. J Biol Chem 2004; 279: 34614-34623. (Pubitemid 39318091)
15. Yadav PN, Abbas AI, Farrell MS, Setola V, Sciaky N, Huang XP et al. The presynaptic component of the serotonergic system is required for clozapine's efficacy. Neuropsychopharmacology 2011; 36: 638-651.
16. Abbas AI, Yadav PN, Yao WD, Arbuckle MI, Grant SG, Caron MG et al. PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J Neurosci 2009; 29: 7124-7136.
17. Farber NB. The NMDA receptor hypofunction model of psychosis. Ann NY Acad Sci 2003; 1003: 119-130. (Pubitemid 38083050)
18. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology (Berl) 2001; 156: 117-154. (Pubitemid 32702206)
19. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron 2003; 40: 881-884. (Pubitemid 37522046)
20. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 1959; 81: 363-369.
21. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13: 9-19.
22. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001; 276: 38121-38138.
23. Linn GS, Javitt DC. Phencyclidine (PCP)-induced deficits of prepulse inhibition in monkeys. Neuroreport 2001; 12: 117-120. (Pubitemid 32099039)
24. Genedani S, Guidolin D, Leo G, Filaferro M, Torvinen M, Woods AS et al. Computerassisted image analysis of caveolin-1 involvement in the internalization process of adenosine A2A-dopamine D2 receptor heterodimers. J Mol Neurosci 2005; 26: 177-184. (Pubitemid 41389410)
25. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989; 251: 238-246.
26. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004; 3: 353-359. (Pubitemid 38499762)
27. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ et al. Predicting new molecular targets for known drugs. Nature 2009; 462: 175-181.
28. Glennon RA. Do classical hallucinogens act as 5-HT2 agonists or antagonists? Neuropsychopharmacology 1990; 3: 509-517.
29. Gonzalez-Maeso J, Yuen T, Ebersole BJ,Wurmbach E, Lira A, Zhou M et al. Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci 2003; 23: 8836-8843. (Pubitemid 37210895)
30. Strachan RT, Allen JA, Sheffler DJ, Roth BL. p90 Ribosomal S6 kinase 2, a novel GPCR kinase, is required for growth factor-mediated attenuation of GPCR signaling. Biochemistry 2010; 49: 2657-2671.
31. Owen MJ, Williams HJ, O'Donovan MC. Schizophrenia genetics: Advancing on two fronts. Curr Opin Genet Dev 2009; 19: 266-270.
32. Fernandez E, Collins MO, Uren RT, Kopanitsa MV, Komiyama NH, Croning MD et al. Targeted tandem affinity purification of PSD-95 recovers core postsynaptic complexes and schizophrenia susceptibility proteins. Mol Syst Biol 2009; 5: 269.
33. Bayes A, van de Lagemaat LN, Collins MO, Croning MD, Whittle IR, Choudhary JS et al. Characterization of the proteome, diseases and evolution of the human postsynaptic density. Nat Neurosci 2011; 14: 19-21.
34. Mukai J, Dhilla A, Drew LJ, Stark KL, Cao L, MacDermott AB et al. Palmitoylationdependent neurodevelopmental deficits in a mouse model of 22q11 microdeletion. Nat Neurosci 2008; 11: 1302-1310.
35. Takayasu Y, Takeuchi K, Kumari R, Bennett MV, Zukin RS, Francesconi A. Caveolin-1 knockout mice exhibit impaired induction of mGluR-dependent long-term depression at CA3-CA1 synapses. Proc Natl Acad Sci U S A 2010; 107: 21778-21783.
36. Head BP, Patel HH, Tsutsumi YM, Hu Y, Mejia T, Mora RC et al. Caveolin-1 expression is essential for N-methyl-D-aspartate receptor-mediated Src and extracellular signalregulated kinase 1/2 activation and protection of primary neurons from ischemic cell death. FASEB J 2008; 22: 828-840. (Pubitemid 351348135)